Product Highlight - Jemperli

The first immunotherapy approved for recurrent/advanced dMMR/MSI-H endometrial cancer¹

• JEMPERLI is indicated as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen¹
• Significant efficacy (45.5% ORR and 60.1% DCR) demonstrated with sustained benefits^2,3
• A well-tolerated treatment choice³
• The only PD-1 therapy clinically tested with a Q6W dosing schedule in endometrial cancer³

Abbreviations: DCR, disease control rate; dMMR, mismatch repair deficient; MSI-H, microsatellite instability-high; ORR, objective response rate; PD-1, programmed death-1; Q6W, every 6 weeks.

References:
1. JEMPERLI (dostarlimab) [prescribing information]. GlaxoSmithKline; 2021.
2. Oaknin A, et al. JAMA Oncol 2020;6:1766-1772.
3. Oaknin A, et al. Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability–high or proficient/stable endometrial cancer: the GARNET study. Presented at: 2022 ASCO Annual Meeting; 3–7 June 2022; Chicago, IL, USA.